|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: Recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stojdl DF, Lichty B, Knowles S, Marius R,
Atkins H, Sonenberg N and Bell JC: Exploiting tumor-specific
defects in the interferon pathway with a previously unknown
oncolytic virus. Nat Med. 6:821–825. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Balachandran S, Porosnicu M and Barber GN:
Oncolytic activity of vesicular stomatitis virus is effective
against tumors exhibiting aberrant p53, Ras, or myc function and
involves the induction of apoptosis. J Virol. 75:3474–3479. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ebert O, Shinozaki K, Huang TG, Savontaus
MJ, García-Sastre A and Woo SL: Oncolytic vesicular stomatitis
virus for treatment of orthotopic hepatocellular carcinoma in
immune-competent rats. Cancer Res. 63:3605–3611. 2003.PubMed/NCBI
|
|
6
|
Li Q, Wei YQ, Wen YJ, Zhao X, Tian L, Yang
L, Mao YQ, Kan B, Wu Y, Ding ZY, et al: Induction of apoptosis and
tumor regression by vesicular stomatitis virus in the presence of
gemcitabine in lung cancer. Int J Cancer. 112:143–149. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin X, Chen X, Wei Y, Zhao J, Fan L, Wen
Y, Wu H and Zhao X: Efficient inhibition of intraperitoneal human
ovarian cancer growth and prolonged survival by gene transfer of
vesicular stomatitis virus matrix protein in nude mice. Gynecol
Oncol. 104:540–546. 2007. View Article : Google Scholar
|
|
8
|
Du XB, Lang JY, Xu JR, Lu Y, Wen YJ, Zhao
JM, Diao P, Yuan ZP, Yao B, Fan LY, et al: Vesicular stomatitis
virus matrix protein gene enhances the antitumor effects of
radiation via induction of apoptosis. Apoptosis. 13:1205–1214.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stewart JH IV, Ahmed M, Northrup SA,
Willingham M and Lyles DS: Vesicular stomatitis virus as a
treatment for colorectal cancer. Cancer Gene Ther. 18:837–849.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wong LH, Krauer KG, Hatzinisiriou I,
Estcourt MJ, Hersey P, Tam ND, Edmondson S, Devenish RJ and Ralph
SJ: Interferon-resistant human melanoma cells are deficient in
ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem.
272:28779–28785. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moussavi M, Fazli L, Tearle H, Guo Y, Cox
M, Bell J, Ong C, Jia W and Rennie PS: Oncolysis of prostate
cancers induced by vesicular stomatitis virus in PTEN knockout
mice. Cancer Res. 70:1367–1376. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gyrd-Hansen M and Meier P: IAPs: From
caspase inhibitors to modulators of NF-kappaB, inflammation and
cancer. Nat Rev Cancer. 10:561–574. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vucic D, Stennicke HR, Pisabarro MT,
Salvesen GS and Dixit VM: ML-IAP, a novel inhibitor of apoptosis
that is preferentially expressed in human melanomas. Curr Biol.
10:1359–1366. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin JH, Deng G, Huang Q and Morser J:
KIAP, a novel member of the inhibitor of apoptosis protein family.
Biochem Biophys Res Commun. 279:820–831. 2000. View Article : Google Scholar
|
|
15
|
Ashhab Y, Alian A, Polliack A, Panet A and
Ben Yehuda D: Two splicing variants of a new inhibitor of apoptosis
gene with different biological properties and tissue distribution
pattern. FEBS Lett. 495:56–60. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tanabe H, Yagihashi A, Tsuji N, Shijubo Y,
Abe S and Watanabe N: Expression of survivin mRNA and livin mRNA in
non-small-cell lung cancer. Lung Cancer. 46:299–304. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gazzaniga P, Gradilone A, Giuliani L,
Gandini O, Silvestri I, Nofroni I, Saccani G, Frati L and Aglianò
AM: Expression and prognostic significance of LIVIN, SURVIVIN and
other apoptosis-related genes in the progression of superficial
bladder cancer. Ann Oncol. 14:85–90. 2003. View Article : Google Scholar
|
|
18
|
Choi J, Hwang YK, Sung KW, Lee SH, Yoo KH,
Jung HL, Koo HH, Kim HJ, Kang HJ, Shin HY, et al: Expression of
Livin, an antiapoptotic protein, is an independent favorable
prognostic factor in childhood acute lymphoblastic leukemia. Blood.
109:471–477. 2007. View Article : Google Scholar
|
|
19
|
Xiang Y, Yao H, Wang S, Hong M, He J, Cao
S, Min H, Song E and Guo X: Prognostic value of Survivin and Livin
in nasopharyngeal carcinoma. Laryngoscope. 116:126–130. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gong J, Chen N, Zhou Q, Yang B, Wang Y and
Wang X: Melanoma inhibitor of apoptosis protein is expressed
differentially in melanoma and melanocytic naevus, but similarly in
primary and metastatic melanomas. J Clin Pathol. 58:1081–1085.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ding ZY, Liu GH, Olsson B and Sun XF:
Upregulation of the antiapoptotic factor Livin contributes to
cisplatin resistance in colon cancer cells. Tumour Biol.
34:683–693. 2013. View Article : Google Scholar
|
|
22
|
Liu GH, Wang C and Ding ZY: Overexpression
of the truncated form of Livin reveals a complex interaction with
caspase-3. Int J Oncol. 42:2037–2045. 2013.PubMed/NCBI
|
|
23
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Luo J, Solimini NL and Elledge SJ:
Principles of cancer therapy: Oncogene and non-oncogene addiction.
Cell. 136:823–837. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kopecky SA and Lyles DS: Contrasting
effects of matrix protein on apoptosis in HeLa and BHK cells
infected with vesicular stomatitis virus are due to inhibition of
host gene expression. J Virol. 77:4658–4669. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gadaleta P, Perfetti X, Mersich S and
Coulombié F: Early activation of the mitochondrial apoptotic
pathway in Vesicular Stomatitis virus-infected cells. Virus Res.
109:65–69. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gaddy DF and Lyles DS: Oncolytic vesicular
stomatitis virus induces apoptosis via signaling through PKR, Fas,
and Daxx. J Virol. 81:2792–2804. 2007. View Article : Google Scholar :
|
|
28
|
Tumilasci VF, Olière S, Nguyên TL, Shamy
A, Bell J and Hiscott J: Targeting the apoptotic pathway with BCL-2
inhibitors sensitizes primary chronic lymphocytic leukemia cells to
vesicular stomatitis virus-induced oncolysis. J Virol.
82:8487–8499. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Igney FH and Krammer PH: Death and
anti-death: Tumour resistance to apoptosis. Nat Rev Cancer.
2:277–288. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schache P, Gürlevik E, Strüver N, Woller
N, Malek N, Zender L, Manns M, Wirth T, Kühnel F and Kubicka S: VSV
virotherapy improves chemotherapy by triggering apoptosis due to
proteasomal degradation of Mcl-1. Gene Ther. 16:849–861. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vucic D, Franklin MC, Wallweber HJ, Das K,
Eckelman BP, Shin H, Elliott LO, Kadkhodayan S, Deshayes K,
Salvesen GS, et al: Engineering ML-IAP to produce an
extraordinarily potent caspase 9 inhibitor: Implications for
Smac-dependent anti-apoptotic activity of ML-IAP. Biochem J.
385:11–20. 2005. View Article : Google Scholar :
|
|
32
|
Wu H, Tschopp J and Lin SC: Smac mimetics
and TNFalpha: A dangerous liaison? Cell. 131:655–658. 2007.
View Article : Google Scholar : PubMed/NCBI
|
